Aernoud Fiolet

147 Colchicine in Patients with Chronic Coronary Disease Table S2 LoDoCo2 Trial End Points A: Ranked primary and secondary end points, and additional end points Ranking End Point Primary 1 The composite of cardiovascular death, myocardial infarction, ischemic stroke or ischemia-driven coronary revascularization Secondary 2 The composite of cardiovascular death, myocardial infarction or ischemic stroke 3 The composite of myocardial infarction or ischemia-driven coronary revascularization 4 The composite of cardiovascular death or myocardial infarction 5 Ischemia-driven coronary revascularization 6 Myocardial infarction 7 Ischemic stroke 8 Death from any cause 9 Cardiovascular death Additional - The primary end point of the first LoDoCo trial: sudden cardiac death, non-fatal out of hospital cardiac arrest, acute coronary syndrome (myocardial infarction or unstable angina irrespective of revascularization), or atherosclerotic ischemic stroke - New onset or first recurrence of atrial fibrillation or atrial flutter - Deep vein thrombosis and/or pulmonary embolism - All myocardial infarction - New onset diabetes